Evidence map›Paper›PMID 32353252›Full record

ArticleCell2020

Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza.

Timothy R Abbott, Girija Dhamdhere, Yanxia Liu, Xueqiu Lin, Laine Goudy, Leiping Zeng, Augustine Chemparathy, Stephen Chmura, Nicholas S Heaton, Robert Debs and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 300 papers.

0numbers the graph read from it
0cells of the map it votes in
300citing papers in PubMed
31.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

300 citing papers in PubMed, 493 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review

240 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Timothy R AbbottDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Girija DhamdhereDepartment of Pediatrics, Stanford University, Stanford, CA 94305, USA.
Yanxia LiuDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Xueqiu LinDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Laine GoudyDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Leiping ZengDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Augustine ChemparathyDepartment of Management Science and Engineering, Stanford University, Stanford, CA 94305, USA.
Stephen ChmuraDNARx, San Francisco, CA 94107, USA.
Nicholas S HeatonDepartment of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC 27710, USA.
Robert DebsDNARx, San Francisco, CA 94107, USA.
Tara PandeLos Altos High School, Los Altos, CA 94022, USA.
Drew EndyDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA.
Marie F La RussaDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA. Electronic address: mlarussa@stanford.edu.
David B LewisDepartment of Pediatrics, Stanford University, Stanford, CA 94305, USA. Electronic address: dblewis@stanford.edu.
Lei S QiDepartment of Bioengineering, Stanford University, Stanford, CA 94305, USA; Department of Chemical and Systems Biology, Stanford University, Stanford, CA 94305, USA; ChEM-H, Stanford University, Stanford, CA 94305, USA. Electronic address: stanley.qi@stanford.edu.
Stanford University · USDNARx (United States) · USDuke University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coronavirus disease 2019 (COVID-19) pandemic, caused by the SARS-CoV-2 virus, has highlighted the need for antiviral approaches that can target emerging viruses with no effective vaccines or pharmaceuticals. Here, we demonstrate a CRISPR-Cas13-based strategy, PAC-MAN (prophylactic antiviral CRISPR in human cells), for viral inhibition that can effectively degrade RNA from SARS-CoV-2 sequences and live influenza A virus (IAV) in human lung epithelial cells. We designed and screened CRISPR RNAs (crRNAs) targeting conserved viral regions and identified functional crRNAs targeting SARS-CoV-2. This approach effectively reduced H1N1 IAV load in respiratory epithelial cells. Our bioinformatic analysis showed that a group of only six crRNAs can target more than 90% of all coronaviruses. With the development of a safe and effective system for respiratory tract delivery, PAC-MAN has the potential to become an important pan-coronavirus inhibition strategy.

Indexed as

CRISPR-Cas SystemsA549 CellsAntibiotic ProphylaxisAntiviral AgentsBase SequenceBetacoronavirusClustered Regularly Interspaced Short Palindromic RepeatsComputer SimulationConserved SequenceCoronavirusCoronavirus InfectionsCoronavirus Nucleocapsid ProteinsCoronavirus RNA-Dependent RNA PolymeraseCOVID-19Epithelial CellsHumansAntiviral AgentsCoronavirus Nucleocapsid ProteinsCoronavirus RNA-Dependent RNA PolymeraseNSP12 protein, SARS-CoV-2nucleocapsid phosphoprotein, SARS-CoV-2Nucleocapsid ProteinsPhosphoproteinsRNA-Dependent RNA PolymeraseRNA, ViralViral Nonstructural Proteins2019-nCoVantiviralCas13COVID-19CRISPRIAVinfluenzanucleocapsidRdRPSARS-CoV-2

Identifiers

PMID32353252
PMCPMC7189862
OpenAlexW3016048690

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.